دورية أكاديمية
أعرض في EDS

Clinical significance of P-class pumps in cancer.

التفاصيل البيبلوغرافية
العنوان: Clinical significance of P-class pumps in cancer.
المؤلفون: Themistocleous SC; Department of Medicine, School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus., Yiallouris A; Department of Medicine, School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus., Tsioutis C; Department of Medicine, School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus., Zaravinos A; Department of Life Sciences, School of Sciences, European University Cyprus, 2404 Nicosia, Cyprus.; College of Medicine, Member of Qatar University Health, Qatar University, 2713 Doha, Qatar., Johnson EO; Department of Medicine, School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus., Patrikios I; Department of Medicine, School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus.
المصدر: Oncology letters [Oncol Lett] 2021 Sep; Vol. 22 (3), pp. 658. Date of Electronic Publication: 2021 Jul 12.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Spandidos Publications] Country of Publication: Greece NLM ID: 101531236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1792-1082 (Electronic) Linking ISSN: 17921074 NLM ISO Abbreviation: Oncol Lett Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Athens : Spandidos Publications]
مستخلص: P-class pumps are specific ion transporters involved in maintaining intracellular/extracellular ion homeostasis, gene transcription, and cell proliferation and migration in all eukaryotic cells. The present review aimed to evaluate the role of P-type pumps [Na + /K + ATPase (NKA), H + /K + ATPase (HKA) and Ca2 + -ATPase] in cancer cells across three fronts, namely structure, function and genetic expression. It has been shown that administration of specific P-class pumps inhibitors can have different effects by: i) Altering pump function; ii) inhibiting cell proliferation; iii) inducing apoptosis; iv) modifying metabolic pathways; and v) induce sensitivity to chemotherapy and lead to antitumor effects. For example, the NKA β2 subunit can be downregulated by gemcitabine, resulting in increased apoptosis of cancer cells. The sarcoendoplasmic reticulum calcium ATPase can be inhibited by thapsigargin resulting in decreased prostate tumor volume, whereas the HKA α subunit can be affected by proton pump inhibitors in gastric cancer cell lines, inducing apoptosis. In conclusion, the present review highlighted the central role of P-class pumps and their possible use and role as anticancer cellular targets for novel therapeutic chemical agents.
Competing Interests: The authors declare that they have no competing interests.
(Copyright: © Themistocleous et al.)
References: Pflugers Arch. 2009 Jan;457(3):609-22. (PMID: 18536934)
J Biol Chem. 1992 Jan 15;267(2):1286-92. (PMID: 1530936)
Subcell Biochem. 2018;87:229-258. (PMID: 29464562)
PLoS One. 2014 Oct 07;9(10):e108776. (PMID: 25290152)
Cancer Sci. 2008 Dec;99(12):2467-76. (PMID: 19037992)
EMBO J. 2002 Jul 1;21(13):3264-73. (PMID: 12093728)
Dis Markers. 2010;28(2):63-9. (PMID: 20364041)
Int J Mol Sci. 2017 Nov 08;18(11):. (PMID: 29117147)
Lancet. 2018 Aug 4;392(10145):400-408. (PMID: 30057104)
FEBS Lett. 1993 Aug 16;328(3):253-8. (PMID: 8394248)
Mol Carcinog. 2017 Jul;56(7):1703-1711. (PMID: 28150875)
Gastroenterology. 2007 Sep;133(3):755-60. (PMID: 17678921)
Naunyn Schmiedebergs Arch Pharmacol. 2012 Mar;385(3):277-86. (PMID: 22113419)
Oncol Lett. 2013 Aug;6(2):475-479. (PMID: 24137350)
Cell Death Dis. 2016 Jan 28;7:e2070. (PMID: 26821066)
Histol Histopathol. 2008 Apr;23(4):459-67. (PMID: 18228203)
Physiol Rev. 1987 Oct;67(4):1296-331. (PMID: 2446342)
Integr Cancer Ther. 2007 Dec;6(4):354-64. (PMID: 18048883)
Met Ions Life Sci. 2016;16:459-83. (PMID: 26860309)
J Neurosci. 2013 Jun 12;33(24):9913-9. (PMID: 23761886)
Cell Death Dis. 2013 Jul 11;4:e720. (PMID: 23846222)
Biochemistry. 1999 Nov 9;38(45):14746-51. (PMID: 10555956)
Oncol Res. 2017 Mar 13;25(3):317-329. (PMID: 28281974)
Physiol Rep. 2018 Sep;6(17):e13843. (PMID: 30175537)
J Biol Chem. 1994 Mar 11;269(10):7571-8. (PMID: 8125980)
Cardiovasc Res. 1999 Aug 1;43(2):371-81. (PMID: 10536667)
Am J Cancer Ther Pharmacol. 2014 Sep 7;2(1):21-32. (PMID: 25580468)
Therap Adv Gastroenterol. 2019 Mar 11;12:1756284819834511. (PMID: 30886648)
Mol Cancer Res. 2019 Jan;17(1):238-249. (PMID: 30206184)
Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1982-8. (PMID: 15563542)
Clin Cancer Res. 2018 Apr 1;24(7):1677-1690. (PMID: 29279319)
F1000Res. 2017 Jan 5;6:10. (PMID: 28529692)
Clin Cancer Res. 2004 Dec 15;10(24):8687-96. (PMID: 15623654)
Protein Cell. 2014 Jul;5(7):532-43. (PMID: 24715268)
Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2502-11. (PMID: 25150047)
Neuro Oncol. 2013 Nov;15(11):1518-31. (PMID: 23887941)
Oncol Lett. 2014 Feb;7(2):393-398. (PMID: 24396454)
J Clin Gastroenterol. 2007 Jul;41 Suppl 2:S226-42. (PMID: 17575528)
Mol Med Rep. 2016 May;13(5):4461-8. (PMID: 27035431)
Acta Pharm. 2020 Jun 1;70(2):179-190. (PMID: 31955147)
J Bioenerg Biomembr. 2005 Dec;37(6):387-92. (PMID: 16691470)
J Cell Physiol. 1994 Jul;160(1):113-20. (PMID: 8021291)
Oncotarget. 2016 Apr 26;7(17):24415-28. (PMID: 27027435)
Biochim Biophys Acta. 1998 Jun 10;1365(1-2):37-45. (PMID: 9693719)
Eur J Biochem. 2001 May;268(10):2873-80. (PMID: 11358503)
Mol Carcinog. 2014 Apr;53(4):253-63. (PMID: 23073998)
Pharm Pat Anal. 2012 Mar;1(1):91-106. (PMID: 24236716)
J Gastroenterol Hepatol. 2005 Aug;20(8):1266-78. (PMID: 16048577)
Clin Chem. 2007 Jul;53(7):1315-22. (PMID: 17495020)
Biomolecules. 2012 Mar 05;2(1):165-86. (PMID: 24970132)
J Biol Chem. 2005 May 13;280(19):19003-11. (PMID: 15755730)
J Biol Chem. 1996 Sep 13;271(37):22754-8. (PMID: 8798450)
Biochem Biophys Res Commun. 2004 Jun 25;319(2):312-20. (PMID: 15178408)
FEBS J. 2013 Nov;280(21):5408-18. (PMID: 23157274)
Biomed Pharmacother. 2014 Oct;68(8):1141-8. (PMID: 25458791)
Cancer Prev Res (Phila). 2019 Oct;12(10):653-666. (PMID: 31431500)
Neoplasia. 2017 Aug;19(8):649-658. (PMID: 28732212)
Cell Physiol Biochem. 2016;39(4):1404-20. (PMID: 27606689)
Acta Pharmacol Sin. 2004 Apr;25(4):474-9. (PMID: 15066216)
Am J Pharm Educ. 2006 Oct 15;70(5):101. (PMID: 17149430)
J Pharm Pharm Sci. 2014;17(3):439-46. (PMID: 25224353)
Annu Rev Biochem. 2020 Jun 20;89:583-603. (PMID: 31874046)
Nature. 2000 Jun 8;405(6787):647-55. (PMID: 10864315)
Curr Med Chem. 2009;16(1):66-93. (PMID: 19149563)
Sci Rep. 2016 Feb 05;6:20442. (PMID: 26847162)
Clin Pharmacol Drug Dev. 2015 Nov;4(6):449-53. (PMID: 27137717)
Front Cell Neurosci. 2015 Mar 17;9:86. (PMID: 25852478)
Brain Res Mol Brain Res. 2004 Jun 18;125(1-2):105-12. (PMID: 15193427)
Biochim Biophys Acta. 2009 May;1787(5):335-44. (PMID: 19268425)
J Natl Cancer Inst. 2003 Jul 2;95(13):990-1000. (PMID: 12837835)
Rev Physiol Biochem Pharmacol. 2003;150:1-35. (PMID: 12811587)
Annu Rev Biophys. 2011;40:243-66. (PMID: 21351879)
Exp Eye Res. 2013 Oct;115:113-22. (PMID: 23810808)
Medicine (Baltimore). 2016 Mar;95(11):e2698. (PMID: 26986096)
Sci Rep. 2018 Aug 24;8(1):12732. (PMID: 30143663)
Eur Respir J. 1998 Mar;11(3):758-66. (PMID: 9596133)
Invest New Drugs. 2013 Aug;31(4):1087-94. (PMID: 23748872)
Front Physiol. 2016 Jan 29;7:9. (PMID: 26858653)
Cell Physiol Biochem. 2014;34(5):1507-26. (PMID: 25322912)
Cell Calcium. 2018 Jan;69:46-61. (PMID: 28747251)
Nutrients. 2017 Nov 10;9(11):. (PMID: 29125563)
Int J Mol Sci. 2012;13(4):5019-34. (PMID: 22606027)
Oncotarget. 2016 Feb 2;7(5):6074-87. (PMID: 26756216)
Pharmacol Ther. 2016 Dec;168:12-22. (PMID: 27514776)
J Exp Biol. 1995 Jan;198(Pt 1):1-17. (PMID: 7891030)
Biochem Biophys Res Commun. 2016 Dec 2;481(1-2):7-12. (PMID: 27836549)
Future Oncol. 2005 Dec;1(6):779-86. (PMID: 16556057)
J Biol Chem. 2004 Jul 16;279(29):30888-95. (PMID: 15133029)
Annu Rev Biochem. 2002;71:511-35. (PMID: 12045105)
Laryngoscope. 2021 Jan;131(1):130-135. (PMID: 32250454)
Cancer Res. 2000 Jul 15;60(14):3807-12. (PMID: 10919654)
Neoplasia. 2017 Apr;19(4):255-260. (PMID: 28278423)
Front Physiol. 2017 Jun 06;8:371. (PMID: 28634454)
Fitoterapia. 2013 Sep;89:210-7. (PMID: 23742858)
Cancer Lett. 2013 Jul 28;335(2):479-86. (PMID: 23507557)
Cell Physiol Biochem. 2011;28(6):1287-94. (PMID: 22179016)
Mol Cancer Ther. 2010 Jun;9(6):1515-24. (PMID: 20501797)
Mol Cancer Ther. 2011 Nov;10(11):2083-93. (PMID: 21859838)
Biochim Biophys Acta. 2016 Jun;1863(6 Pt B):1344-50. (PMID: 26608610)
Adv Ther. 2016 Jul;33(7):1140-57. (PMID: 27287852)
EMBO J. 2009 Jun 3;28(11):1637-43. (PMID: 19387495)
Oncotarget. 2016 Sep 27;7(39):62925-62938. (PMID: 26910837)
Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8414-18. (PMID: 1326755)
Paediatr Drugs. 2013 Apr;15(2):119-31. (PMID: 23512128)
Br J Cancer. 2016 Apr 26;114(9):986-94. (PMID: 27115568)
Biochem Pharmacol. 2004 Feb 15;67(4):727-33. (PMID: 14757172)
Am J Cancer Res. 2019 Jun 01;9(6):1293-1308. (PMID: 31285960)
Bioorg Med Chem. 2006 Apr 15;14(8):2810-5. (PMID: 16412648)
Biol Pharm Bull. 2007 Apr;30(4):648-54. (PMID: 17409496)
Neurochem Int. 2019 Sep;128:163-174. (PMID: 31009649)
Br J Pharmacol. 2009 Apr;156(7):1054-66. (PMID: 19298255)
Curr Med Chem. 2012;19(5):627-46. (PMID: 22204337)
Cancer Biol Ther. 2005 Jan;4(1):14-22. (PMID: 15662118)
J Exp Clin Cancer Res. 2014 Sep 01;33:73. (PMID: 25175076)
Oncol Rep. 2011 Mar;25(3):825-30. (PMID: 21181095)
Oncotarget. 2017 Jan 17;8(3):4147-4155. (PMID: 27926505)
Cancers (Basel). 2020 Mar 10;12(3):. (PMID: 32164284)
J Biol Chem. 1995 Feb 3;270(5):2176-82. (PMID: 7836447)
Int J Oncol. 2004 Jan;24(1):97-105. (PMID: 14654946)
Cancers (Basel). 2020 Jun 19;12(6):. (PMID: 32575381)
Biochem Biophys Rep. 2016 Jun 30;7:253-258. (PMID: 28955914)
Oncol Lett. 2014 Aug;8(2):517-522. (PMID: 25013464)
Brain Res Mol Brain Res. 2001 Jan 31;86(1-2):189-92. (PMID: 11165386)
World J Gastroenterol. 2009 Aug 28;15(32):4016-22. (PMID: 19705497)
Nat Rev Mol Cell Biol. 2004 Apr;5(4):282-95. (PMID: 15071553)
J Transl Med. 2013 Oct 24;11:268. (PMID: 24156349)
J Struct Biol. 2012 Apr;178(1):38-44. (PMID: 22387132)
Mol Cancer. 2015 May 15;14:105. (PMID: 25976744)
Oncotarget. 2017 Jun 16;8(35):58801-58808. (PMID: 28938598)
J Bioenerg Biomembr. 2007 Dec;39(5-6):349-55. (PMID: 18175209)
Oncol Lett. 2014 Oct;8(4):1739-1744. (PMID: 25202402)
J Biol Chem. 2005 Nov 11;280(45):37717-24. (PMID: 16148001)
Biochem Biophys Res Commun. 2011 Sep 9;412(4):543-8. (PMID: 21855530)
Basic Clin Pharmacol Toxicol. 2020 Jun;126(6):484-491. (PMID: 31872571)
J Biol Chem. 1994 Aug 5;269(31):19659-62. (PMID: 8051040)
Cancer Inform. 2015 Oct 12;14:113-9. (PMID: 26494976)
J Biol Chem. 2011 Sep 16;286(37):32394-403. (PMID: 21784855)
Int J Mol Sci. 2020 Dec 22;22(1):. (PMID: 33374919)
فهرسة مساهمة: Keywords: HKA; NKA; P-type ATPases; SERCA; cancer; pump subunits
تواريخ الأحداث: Date Created: 20210813 Latest Revision: 20210814
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8298992
DOI: 10.3892/ol.2021.12919
PMID: 34386080
قاعدة البيانات: MEDLINE
الوصف
تدمد:1792-1082
DOI:10.3892/ol.2021.12919